Back to results
US 2025/0018047 A1Published application
Methods and compositions for targeted protein degradation
AssigneeRanok Therapeutics (Hangzhou) Co. Ltd.
InventorsWeiwen Ying, Chenghao Ying, Kevin P. Foley, Lingjie Zhang, Mingkai Wang, Long Ye, Thomas Prince, Wei Yin, Yaya Wang
Life of this patent
Estimating the term…
Abstract
Provided are PROTACs comprised of a targeting moiety designed to bind KRAS (G12D) linked to a degrader-directing moiety designed to bind an E3 ubiquitin-ligase. Pharmaceutical compositions comprising the disclosed PROTACs and their use in treating cancer and related conditions are also provided.
Claims20
A compound of the Formula I:
- or a pharmaceutically acceptable salt thereof, wherein
- HET is an optionally substituted heterocyclyl;
- Ar is an optionally substituted aryl or optionally substituted heteroaryl;
- X is hydrogen or halo;
- L is a linker;
- and
- E is a chemical moiety that targets E3 ligase.
4 more elements
Dependencies are inferred from the claim text.